VaxInnate Corp., a Cranbury, N.J.-based developer of vaccines for both pandemic and seasonal influenza, is almost done raising $30 million in new Series C funding, according to VentureWire. The company held an initial $40 million close on the round back in 2006, led by New Leaf Venture Partners.
